<?xml version="1.0"?>
<?xml-stylesheet type="text/css" href="http://www.feuxdelamour.com/v4/skins/common/feed.css?303"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="fr">
		<id>http://www.feuxdelamour.com/v4/index.php?action=history&amp;feed=atom&amp;title=My_Ostentatious_INK_128_Conspriracy</id>
		<title>My Ostentatious INK 128 Conspriracy - Historique des versions</title>
		<link rel="self" type="application/atom+xml" href="http://www.feuxdelamour.com/v4/index.php?action=history&amp;feed=atom&amp;title=My_Ostentatious_INK_128_Conspriracy"/>
		<link rel="alternate" type="text/html" href="http://www.feuxdelamour.com/v4/index.php?title=My_Ostentatious_INK_128_Conspriracy&amp;action=history"/>
		<updated>2026-07-14T12:04:10Z</updated>
		<subtitle>Historique pour cette page sur le wiki</subtitle>
		<generator>MediaWiki 1.20alpha</generator>

	<entry>
		<id>http://www.feuxdelamour.com/v4/index.php?title=My_Ostentatious_INK_128_Conspriracy&amp;diff=52904&amp;oldid=prev</id>
		<title>Cloth59butter : Page créée avec « The total number of RLNs was the total number of dissected axillary lymph nodes. The LODDS was defined as loge ([pnod + 0.5]/[tnod + 0.5]), where pnod is the number of pos... »</title>
		<link rel="alternate" type="text/html" href="http://www.feuxdelamour.com/v4/index.php?title=My_Ostentatious_INK_128_Conspriracy&amp;diff=52904&amp;oldid=prev"/>
				<updated>2016-12-30T19:08:24Z</updated>
		
		<summary type="html">&lt;p&gt;Page créée avec « The total number of RLNs was the total number of dissected axillary lymph nodes. The LODDS was defined as loge ([pnod + 0.5]/[tnod + 0.5]), where pnod is the number of pos... »&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Nouvelle page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;The total number of RLNs was the total number of dissected axillary lymph nodes. The LODDS was defined as loge ([pnod + 0.5]/[tnod + 0.5]), where pnod is the number of positive lymph nodes, tnod is the total number of lymph nodes harvested, and 0.5 is added to both numerator and denomination to avoid singularity [14]. Follow-up and survival endpoints Follow up was performed every 3-6 months by hospital visit, telephone, or mail after surgery. The endpoints of the study were disease-free survival (DFS) and overall survival (OS). For patients with disease recurrence, survival time was determined from [https://en.wikipedia.org/wiki/Quinapyramine Quinapyramine] the date of surgery to the date of locoregional recurrence and/or distant metastasis. OS was calculated as the period from the date of diagnosis to the date of death from any cause or the date of last follow-up. Statistical analysis The ��2 and Fisher��s exact tests were used to analyze the differences between qualitative data. The variance inflation factor (VIF) was used to identify multicollinearity of pN, RLNs, NLNs, LNR, and LODDS; a VIF of �� 10 indicates multicollinearity. Univariate and multivariate Cox regression analyses were performed. Cut-off point analyses were [http://www.selleckchem.com/products/incb28060.html Capmatinib mw] then performed to determine whether there was a cut-off that was related to the greatest difference in DFS and OS. In this analysis, we sequentially dichotomized patients using thresholds of 9-16 NLNs (the interquartile range of NLN count for all patients) with an interval of 1 node (i.e., 9 or fewer nodes vs. more than 9; 10 or fewer nodes vs. more than 10; etc.), and then performed a series of log-rank tests, with the highest ��2 statistic representing the greatest group difference. Calculation of survival rates were plotted by the Kaplan-Meier method, and compared using the log-rank test. All data were analyzed the SPSS statistical software package, version 16.0 (IBM Corporation, Armonk, NY, USA). A value of P [http://www.selleckchem.com/products/ink128.html INK 128 order] resection, and survival A total of 2,515 patients with a median age of 47 years (range, 14-92 years) were included in the study, and their characteristics are shown in Table 1. There were 2,417 patients (96.1%) who received a mastectomy, and 98 patients (3.9%) received breast-conserving surgery. Among all patients, 2,294 (91.2%) were T1/T2 stage, 1,439 (57.2%) were ER+, 1,301 (51.7%) were luminal A, and 410 (16.3%) were triple negative subtype. Table 1 Clinical and histopathological characteristics of the 2515 patients The median number of RLNs was 14 (25th percentile 11, 75th percentile 18; range, 1-73). Overall, 1,319 (52.4%) patients had node-negative disease, and 1,196 (47.6%) had nodal metastases. The median number of NLNs was 12 (25th percentile 9, 75th percentile 16; range, 0-40).&lt;/div&gt;</summary>
		<author><name>Cloth59butter</name></author>	</entry>

	</feed>